{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:50Z","timestamp":1788174590298,"version":"build-2803163510"},"reference-count":42,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Olutasidenib, a potent, selective, oral small-molecule inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), is US Food and Drug Administration approved for mIDH1 relapsed\/refractory (R\/R) acute myeloid leukemia based on results from the pivotal cohort of a multiarm phase 1\/2 trial that also enrolled patients with myelodysplastic syndrome (MDS). We report pooled data evaluating olutasidenib as monotherapy or combined with azacitidine in R\/R and treatment-na\u00efve (TN) higher-risk mIDH1 MDS. Twenty-two patients (median age, 74 years; 59% male) with intermediate- to very high-risk MDS (monotherapy, n = 6 [4 R\/R and 2 TN]; combination, n = 16 [11 R\/R and 5 TN]) were analyzed. The most frequent adverse events were fatigue and cytopenias. Differentiation syndrome occurred in 3 patients (14%), including 1 (5%) with grade 3 severity. QT prolongation occurred in 1 patient receiving combination therapy. ORR was 59% (complete remission [CR], 6\/22 [27%]; marrow CR, 7\/22 [32%]) in intent-to-treat (ITT; n = 22) and 68% (CR, 6\/19 [32%]; marrow CR, 7\/19 [37%]) in response-evaluable patients (n = 19). ORR (ITT population) was 33% (2\/6) for monotherapy (3\/6 patients received half the recommended dose or less) and 69% (11\/16) for combination therapy. Median time to response was 2 months (range, 1-13), median duration of response was 14.6 months (95% confidence interval [CI], 5.8-32.8), and median overall survival was 27.2 months (95% CI, 6.9-37). Sixty-two percent and 67% of patients who were transfusion dependent at baseline achieved 56-day red blood cell and platelet transfusion independence, respectively. Olutasidenib with or without azacitidine demonstrated encouraging clinical activity and tolerability in patients with higher-risk mIDH1 MDS. This trial was registered at www.ClinicalTrials.gov as #NCT02719574.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016718","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:47:47Z","timestamp":1752680867000},"page":"5293-5305","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Olutasidenib alone or combined with azacitidine in patients with mutant\n                    <i>IDH1<\/i>\n                    myelodysplastic syndrome"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Medical Oncology, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira N.","family":"Dinner","sequence":"additional","affiliation":[{"name":"4Division of Hematology\/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Tian","sequence":"additional","affiliation":[{"name":"7Rigel Pharmaceuticals, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"di Trapani","sequence":"additional","affiliation":[{"name":"7Rigel Pharmaceuticals, Inc, South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"8Department of Medicine, University of Maryland School of Medicine and University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Donnellan","sequence":"additional","affiliation":[{"name":"9Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5213-5482","authenticated-orcid":false,"given":"Justin M.","family":"Watts","sequence":"additional","affiliation":[{"name":"10Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025102810165145100_bib1","unstructured":"National Cancer Institute\n          . SEER\u2217Explorer: an interactive website for SEER cancer statistics. Accessed 28 July 2025. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/."},{"issue":"10","key":"2025102810165145100_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/ajh.25234","article-title":"Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R","volume":"93","author":"Benton","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"2025102810165145100_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"19","key":"2025102810165145100_bib4","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.3390\/ijms221910232","article-title":"Molecular targeted therapy and immunotherapy for myelodysplastic syndrome","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025102810165145100_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Ganan-Gomez","year":"2022","journal-title":"Nat Med"},{"issue":"suppl","key":"2025102810165145100_bib6","first-page":"138-140","article-title":"High-risk MDS after HMAs","volume":"3","author":"Ad\u00e8s","year":"2019","journal-title":"Hemasphere"},{"issue":"24","key":"2025102810165145100_bib7","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025102810165145100_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"2025102810165145100_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2008-03-143735","article-title":"WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"112","author":"Alessandrino","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2025102810165145100_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ajh.26090","article-title":"Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS\/myeloproliferative neoplasm with RS and thrombocytosis (MDS\/MPN-RS-T) - \"2021 update on diagnosis, risk-stratification, and management\"","volume":"96","author":"Patnaik","year":"2021","journal-title":"Am J Hematol"},{"issue":"25","key":"2025102810165145100_bib11","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025102810165145100_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study [abstract]","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood"},{"issue":"suppl 15","key":"2025102810165145100_bib13","doi-asserted-by":"crossref","first-page":"TPS7082","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7082","article-title":"Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-na\u00efve higher-risk myelodysplastic syndromes [abstract]","volume":"36","author":"Fong","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025102810165145100_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2019-124994","article-title":"A phase 1b study evaluating the safety and efficacy of venetoclax as monotherapy or in combination with azacitidine for the treatment of relapsed\/refractory myelodysplastic syndrome [abstract]","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025102810165145100_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2025102810165145100_bib16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia"},{"issue":"10","key":"2025102810165145100_bib17","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3324\/haematol.2010.025494","article-title":"IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis","volume":"95","author":"Thol","year":"2010","journal-title":"Haematologica"},{"issue":"15","key":"2025102810165145100_bib18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","article-title":"Wild-type and mutated IDH1\/2 enzymes and therapy responses","volume":"37","author":"Molenaar","year":"2018","journal-title":"Oncogene"},{"issue":"11","key":"2025102810165145100_bib19","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"2025102810165145100_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2025102810165145100_bib21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"2025102810165145100_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J Exp Med"},{"issue":"16","key":"2025102810165145100_bib23","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/bloodadvances.2023009854","article-title":"Olutasidenib: from bench to bedside","volume":"7","author":"Venugopal","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025102810165145100_bib24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"7274","key":"2025102810165145100_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"2","key":"2025102810165145100_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH inhibitors in AML-promise and pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"2025102810165145100_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s11864-024-01264-7","article-title":"Looking beyond the surface: olutasidenib and ivosidenib for treatment of mIDH1 acute myeloid leukemia","volume":"25","author":"Watts","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2025102810165145100_bib28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"13","key":"2025102810165145100_bib29","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2025102810165145100_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2025102810165145100_bib31","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"15","key":"2025102810165145100_bib32","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1182\/bloodadvances.2023012302","article-title":"Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed\/refractory myelodysplastic syndrome","volume":"8","author":"DiNardo","year":"2024","journal-title":"Blood Adv"},{"issue":"S1","key":"2025102810165145100_bib33","first-page":"176","article-title":"Ivosidenib monotherapy in IDH1 mutated myelodysplastic syndrome, final results of the IDIOME trial, a GFM study [abstract]","volume":"8","author":"S\u00e9bert","year":"2024","journal-title":"HemaSphere"},{"issue":"5","key":"2025102810165145100_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-021-01367-w","article-title":"Author correction: implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"27","author":"Bernard","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"2025102810165145100_bib35","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","article-title":"The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes","volume":"36","author":"Platzbecker","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"2025102810165145100_bib36","first-page":"392","article-title":"Iron overload in myelodysplastic syndromes: pathophysiology, consequences, diagnosis, and treatment","volume":"9","author":"Lyle","year":"2018","journal-title":"J Adv Pract Oncol"},{"issue":"34","key":"2025102810165145100_bib37","doi-asserted-by":"crossref","first-page":"e11860","DOI":"10.1097\/MD.0000000000011860","article-title":"Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: a systematic review and meta-analysis","volume":"97","author":"Gao","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"2025102810165145100_bib38","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","article-title":"Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia","volume":"29","author":"Fathi","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025102810165145100_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"issue":"16","key":"2025102810165145100_bib40","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025102810165145100_bib41","unstructured":"National Comprehensive Cancer Network\n          . NCCN clinical practice guidelines in oncology (NCCN Guidelines) for myelodysplastic syndromes (MDS) V.2.2025. Accessed 20 August 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf."},{"key":"2025102810165145100_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fonc.2016.00151","article-title":"Unraveling the pathogenesis of MDS: the NLRP3 inflammasome and pyroptosis drive the MDS phenotype","volume":"6","author":"Sallman","year":"2016","journal-title":"Front Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5293\/2417342\/blooda_adv-2025-016718-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5293\/2417342\/blooda_adv-2025-016718-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:30:38Z","timestamp":1761661838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5293\/546206\/Olutasidenib-alone-or-combined-with-azacitidine-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":42,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016718","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,17]]}}}